← Back to Screener
Purple Biotech Ltd. American Depositary Shares (PPBT)
Price$4.95
Favorite Metrics
Price vs S&P 500 (26W)-17.84%
Price vs S&P 500 (4W)-9.49%
Market Capitalization$18.58M
All Metrics
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)2.71x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-12.16%
Net Profit Margin (TTM)-2777.90%
EPS (TTM)$-0.01
10-Day Avg Trading Volume0.73M
EPS Excl Extra (TTM)$-0.01
EPS (Annual)$-0.02
ROI (Annual)-21.91%
Net Profit Margin (5Y Avg)-3987.45%
Cash / Share (Quarterly)$0.01
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-19.55%
Revenue Growth TTM (YoY)0.00%
EBITD / Share (TTM)$-0.01
ROE (5Y Avg)-37.99%
Operating Margin (TTM)-430.20%
Cash Flow / Share (Annual)$-0.03
P/B Ratio0.19x
P/B Ratio (Quarterly)0.20x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-3.07x
Net Interest Coverage (TTM)-0.86x
ROA (TTM)-8.90%
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)2.23x
Quick Ratio (Quarterly)1.78x
3-Month Avg Trading Volume2.96M
52-Week Price Return-45.24%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)6.26x
Asset Turnover (Annual)0.07x
52-Week High$5.70
Operating Margin (5Y Avg)-3437.90%
EPS Excl Extra (Annual)$-0.02
Tangible BV CAGR (5Y)3.38%
26-Week Price Return-9.09%
Quick Ratio (Annual)2.23x
13-Week Price Return-16.67%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)1.78x
Enterprise Value$-3.074
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-34.65%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-567.70%
Cash / Share (Annual)$0.02
3-Month Return Std Dev65.59%
Net Income / Employee (TTM)$-0
ROE (Last FY)-22.03%
Net Interest Coverage (Annual)-205.40x
EPS Basic Excl Extra (Annual)$-0.02
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.01
ROI (TTM)-9.93%
P/S Ratio (TTM)6.26x
Pretax Margin (5Y Avg)-3976.65%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$0.01
Price vs S&P 500 (52W)-42.06%
Year-to-Date Return-9.09%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-32.74%
Net Profit Margin (Annual)-585.00%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-0.53
EBITD / Share (Annual)$-0.03
Operating Margin (Annual)-715.60%
LT Debt / Equity (Annual)0.68x
ROI (5Y Avg)-37.61%
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)1.36x
P/B Ratio (Annual)0.41x
Pretax Margin (TTM)-2781.60%
Book Value / Share (Annual)$0.06
Price vs S&P 500 (13W)-19.53%
Beta0.31x
Revenue / Share (TTM)$0.02
ROE (TTM)-9.98%
52-Week Low$1.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PPBTPurple Biotech Ltd. American Depositary Shares | 6.26x | 0.00% | — | — | $4.95 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Purple Biotech is a clinical-stage oncology company developing first-in-class therapies to overcome drug resistance and immune evasion in cancer. NT219, its lead small molecule candidate, targets IRS1/2 and STAT3 survival pathways associated with drug resistance, while CM24, a monoclonal antibody, blocks CEACAM1 to enhance anti-tumor immune response. Together, these programs address critical mechanisms that allow cancer cells to evade treatment.